
Marcos Oggero

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6814357/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Large Area Microfluidic Bioreactor for Production of Recombinant Protein. Biosensors, 2022, 12, 526.	2.3	2
2	Pharmacokinetics Versus In Vitro Antiproliferative Potency to Design a Novel Hyperglycosylated hIFN-α2 Biobetter. Pharmaceutical Research, 2021, 38, 37-50.	1.7	4
3	Novel erythropoietinâ€based therapeutic candidates with extra <i>N</i> â€glycan sites that block hematopoiesis but preserve neuroplasticity. Biotechnology Journal, 2021, 16, e2000455.	1.8	6
4	Bifunctional GM-CSF-derived peptides as tools for O-glycoengineering and protein tagging. Journal of Biotechnology, 2021, 327, 18-27.	1.9	6
5	Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. Clinical Immunology, 2021, 233, 108888.	1.4	8
6	Identification and characterization of human interferon alpha inhibitors through a WISH cell line-based reporter gene assay. Bioorganic Chemistry, 2020, 94, 103372.	2.0	2
7	The glycosylation of anti-rhIFN-α2b recombinant antibodies influences the antigen-neutralizing activity. Biotechnology Letters, 2020, 42, 1369-1381.	1.1	3
8	Effect of ANITVNITV peptide fusion on the bioactivity and pharmacokinetics of human IFN-α2b and a hyper-N-glycosylated variant. Journal of Biotechnology, 2019, 303, 46-52.	1.9	3
9	Design and validation of an immuno-PCR assay for IFN-α2b quantification in human plasma. Bioanalysis, 2019, 11, 2175-2188.	0.6	2
10	Production of monoclonal antibodies in microfluidic devices. Integrative Biology (United Kingdom), 2018, 10, 136-144.	0.6	9
11	Strategies to Develop Therapeutic N- and O-Hyperglycosylated Proteins. Methods in Molecular Biology, 2018, 1674, 163-181.	0.4	3
12	A highly efficient modified human serum albumin signal peptide to secrete proteins in cells derived from different mammalian species. Protein Expression and Purification, 2017, 132, 27-33.	0.6	25
13	Glycosylation and antiproliferative activity of hyperglycosylated IFN-α2 potentiate HEK293 cells as biofactories. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 119-131.	2.0	13
14	An unusual cysteine V L 87 affects the antibody fragment conformations without interfering with the disulfide bond formation. Molecular Immunology, 2017, 90, 143-149.	1.0	1
15	Screening and characterization of molecules that modulate the biological activity of IFNs-I. Journal of Biotechnology, 2016, 233, 6-16.	1.9	8
16	Improvement of in vitro stability and pharmacokinetics of hIFN-α by fusing the carboxyl-terminal peptide of hCG β-subunit. Journal of Biotechnology, 2016, 221, 13-24.	1.9	17
17	6.2 High Cell Density Cultivation Process. , 2014, , 427-454.		0
18	High performance collection of cerebrospinal fluid in rats: Evaluation of erythropoietin penetration after osmotic opening of the blood–brain barrier. Journal of Neuroscience Methods, 2013, 219, 70-75.	1.3	9

MARCOS OGGERO

#	Article	IF	CITATIONS
19	A versatile ionic strength sensitive tag from a human GM-CSF-derived linear epitope. Protein Expression and Purification, 2013, 91, 10-19.	0.6	2
20	WISH cell line: From the antiviral system to a novel reporter gene assay to test the potency of human IFN-α and IFN-β. Journal of Immunological Methods, 2012, 381, 70-74.	0.6	16
21	Neuroprotective activity of a new erythropoietin formulation with increased penetration in the central nervous system. BMC Proceedings, 2011, 5, P3.	1.8	3
22	New reporter cell clones to determine the biological activity of human type I interferons. BMC Proceedings, 2011, 5, P4.	1.8	5
23	Isolation and characterization of a subset of erythropoietin glycoforms with cytoprotective but minimal erythropoietic activity. Biotechnology Progress, 2011, 27, 1018-1028.	1.3	13
24	Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. Journal of Biotechnology, 2010, 146, 74-83.	1.9	40
25	Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein. Biochimie, 2010, 92, 971-978.	1.3	24
26	Rational selection of an antibody probe to detect the heterogeneous collection of CHO-derived rhGM-CSF glycoforms. Biotechnology Letters, 2006, 28, 2049-2056.	1.1	2
27	N- and O-linked carbohydrates and glycosylation site occupancy in recombinant human granulocyte-macrophage colony-stimulating factor secreted by a Chinese hamster ovary cell line. FEBS Journal, 2004, 271, 907-919.	0.2	39
28	A single monoclonal antibody as probe to detect the entire set of native and partially unfolded rhEPO glycoforms. Journal of Immunological Methods, 2004, 293, 191-205.	0.6	11
29	Defining the antigenic structure of human GM-CSF and its implications for receptor interaction and therapeutic treatments. Molecular Diversity, 2004, 8, 257-269.	2.1	10